Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimecrolimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 18/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | PPP3CA | Q08209 | 2/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.79 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimecrolimus SCHEMBL26411 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL3854625 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL8194907 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL4651515 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL117937 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL436549 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL9947518 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL4456276 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL15277958 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 | |
| Pimecrolimus SCHEMBL10241642 | 1.00 | ABCB11 (1.00) | ABCB11ADORA3FKBP1AFKBP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 728 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024027758-A1 | UNIVERSAL IMMUNE EFFECTOR CELL, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江大学医学院附属第一医院 | 2024-02-08 | — | — | WO | claimed |
| WO-2022047234-A1 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | WO | claimed |
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20260144636-A1 | DELIVERY DEVICE FOR A REPLACEMENT HEART VALVE IMPLANT | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103838-A1 | POLYPEPTIDE COMPLEXES COMPRISING IL-21 VARIANTS AND USES THEREOF | WUXI BIOLOGICS (SHANGHAI) CO., LTD. (CN) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107496-A1 | IMPLANT FOR OCCLUDING A LEFT ATRIAL APPENDAGE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137388-A1 | IMPLANT FOR OCCLUDING A LEFT ATRIAL APPENDAGE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137536-A1 | STENTS, STENT DELIVERY SYSTEMS, AND METHODS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4742997-A1 | OCCLUSIVE IMPLANT SYSTEM | Boston Scientific Scimed, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4745159-A1 | COMPOSITION FOR CELLULAR IMMUNOTHERAPY, AND METHOD | Carsgen Life Sciences Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20070021377-A1 | Pharmaceutical composition comprising a macrolide immunomodulator | GRASSBERGER MAXIMILIAN | 2007-01-25 | — | — | US | disclosed |
| US-20060269608-A1 | Pharmaceutical formulation | NOVARTIS AG (CH) | 2006-11-30 | — | — | US | disclosed |
| US-20060169199-A1 | Crystallization and purification of macrolides | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2006-08-03 | — | — | US | disclosed |
| US-20060147540-A1 | Non-hygroscopic and powdery amorphous pimecrolimus | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2006-07-06 | — | — | US | disclosed |
| US-20060142564-A1 | Methods of preparing pimecrolimus | TEVA PHARMACEUTICALS USA, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060135548-A1 | Processes for producing crystalline macrolides | TEVA CYOGYSZEGYAR ZARTKORUEN MUKODO RESZENYTARSASAG (HU) | 2006-06-22 | — | — | US | disclosed |
| US-20050250805-A1 | Pharmaceutical ointment formulations | GLENMARK PHARMACEUTICALS LIMITED | 2005-11-10 | — | — | US | disclosed |
| WO-2004087144-A1 | COMBINATION OF A MACROLIDE AND A LOCAL ANESTHETIC FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087118-A2 | SYNERGISTIC COMBINATIONS OF MACROLIDE T-CELL MODULATOR OR INMUNOSUPPRESSANT AND A RETINOID | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137388-A1 | IMPLANT FOR OCCLUDING A LEFT ATRIAL APPENDAGE | FABP3, TNNT2, NPPA | FKBP1A 521/4885ABCB11 1407/4885ADORA3 556/4885 |
| US-20260137536-A1 | STENTS, STENT DELIVERY SYSTEMS, AND METHODS | HSPA5, SMC3, SMCHD1 | FKBP1A 1191/4885ABCB11 23/4885ADORA3 4241/4885 |
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | IL1A, IL1R1, FCGR2A | FKBP1A 1626/4885ABCB11 3378/4885ADORA3 3478/4885 |
| US-20070021377-A1 | Pharmaceutical composition comprising a macrolide immunomodulator | SGMS1, SPTLC3, SGMS2 | FKBP1A 1297/4885ABCB11 832/4885ADORA3 3257/4885 |
| US-20060147540-A1 | Non-hygroscopic and powdery amorphous pimecrolimus | PIM1, PIM2, PIM3 | FKBP1A 11/4885ABCB11 2425/4885ADORA3 4782/4885 |
| US-20260144636-A1 | DELIVERY DEVICE FOR A REPLACEMENT HEART VALVE IMPLANT | TNNT2, TNNI3, TPRKB | FKBP1A 2060/4885ABCB11 1240/4885ADORA3 4731/4885 |
| US-20050250805-A1 | Pharmaceutical ointment formulations | PIGS, ABCB11, CUTA | FKBP1A 34/4885ABCB11 2/4885ADORA3 3595/4885 |
| US-20060142564-A1 | Methods of preparing pimecrolimus | ERG28, PIM1, RICTOR | FKBP1A 574/4885ABCB11 543/4885ADORA3 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.